Study of INV-202 in Patients With Obesity and Metabolic Syndrome
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Inversago Pharma Inc.
- Target Recruit Count
- 243
- Registration Number
- NCT05891834
- Locations
- 🇨🇦
Wharton Medical Clinic (WMC) - Toronto, Hamilton, Ontario, Canada
🇨🇦Centricity Research - Mirabel, Mirabel, Quebec, Canada
🇨🇦Aggarwal and Associates, Limited, Brampton, Ontario, Canada
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Inversago Pharma Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT05514548
- Locations
- 🇺🇸
Palm Research Center, Inc, Las Vegas, Nevada, United States
🇮🇱Rambam Health Care Campus \ Rambam Medical Center, Haifa, Israel
🇮🇱Barzilai Medical Center, Ashkelon, Israel
A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Inversago Pharma Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05282446
- Locations
- 🇨🇦
Syneos Health Clinique Inc, Québec, Quebec, Canada
Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Inversago Pharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04531150
- Locations
- 🇨🇦
Altasciences, Montreal, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath